ATE506950T1 - Zusammensetzungen enthaltend metronidazol - Google Patents

Zusammensetzungen enthaltend metronidazol

Info

Publication number
ATE506950T1
ATE506950T1 AT01948497T AT01948497T ATE506950T1 AT E506950 T1 ATE506950 T1 AT E506950T1 AT 01948497 T AT01948497 T AT 01948497T AT 01948497 T AT01948497 T AT 01948497T AT E506950 T1 ATE506950 T1 AT E506950T1
Authority
AT
Austria
Prior art keywords
compositions containing
containing metronidazole
metronidazole
compositions
Prior art date
Application number
AT01948497T
Other languages
German (de)
English (en)
Inventor
Yunik Chang
Gordon Dow
Arturo Angel
Original Assignee
Dow Pharmaceutical Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Pharmaceutical Sciences filed Critical Dow Pharmaceutical Sciences
Application granted granted Critical
Publication of ATE506950T1 publication Critical patent/ATE506950T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT01948497T 2000-07-13 2001-06-19 Zusammensetzungen enthaltend metronidazol ATE506950T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/615,169 US6468989B1 (en) 2000-07-13 2000-07-13 Gel compositions containing metronidazole
PCT/US2001/019644 WO2002006349A1 (en) 2000-07-13 2001-06-19 Gel compositions containing metronidazole

Publications (1)

Publication Number Publication Date
ATE506950T1 true ATE506950T1 (de) 2011-05-15

Family

ID=24464287

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01948497T ATE506950T1 (de) 2000-07-13 2001-06-19 Zusammensetzungen enthaltend metronidazol

Country Status (10)

Country Link
US (1) US6468989B1 (enExample)
EP (1) EP1303541B1 (enExample)
JP (1) JP4130358B2 (enExample)
AR (1) AR030245A1 (enExample)
AT (1) ATE506950T1 (enExample)
AU (1) AU2001269937A1 (enExample)
CA (1) CA2405072C (enExample)
DE (1) DE60144520D1 (enExample)
ES (1) ES2365322T3 (enExample)
WO (1) WO2002006349A1 (enExample)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605751B1 (en) 1997-11-14 2003-08-12 Acrymed Silver-containing compositions, devices and methods for making
EP1244476B1 (en) 1999-12-30 2006-05-31 Acrymed Methods and compositions for improved delivery devices
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US6881726B2 (en) * 2001-12-24 2005-04-19 Dow Pharmaceutical Sciences Aqueous compositions containing metronidazole
CN1678277B (zh) 2002-07-29 2010-05-05 艾克里麦德公司 治疗皮肤病的方法和组合物
US20060140984A1 (en) 2002-10-25 2006-06-29 Foamix Ltd. Cosmetic and pharmaceutical foam
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US8119150B2 (en) * 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US20050090564A1 (en) * 2003-10-28 2005-04-28 Wegener Paul T. Compositions and treatments of bacterial vaginosis
ES2424644T3 (es) 2004-05-25 2013-10-07 Galderma Pharma S.A. Compuestos, formulaciones y métodos para tratar o prevenir los trastornos inflamatorios de la piel
FR2887149B1 (fr) * 2005-06-17 2007-08-03 Galderma Sa Procede de solubilisation du metronidazole
US8361553B2 (en) 2004-07-30 2013-01-29 Kimberly-Clark Worldwide, Inc. Methods and compositions for metal nanoparticle treated surfaces
EP2789235B1 (en) 2004-07-30 2015-12-23 Avent, Inc. Method of preparing silver nanoparticles
CN102783499A (zh) 2004-07-30 2012-11-21 金伯利-克拉克环球有限公司 抗微生物的装置和组合物
US9289378B2 (en) 2004-09-20 2016-03-22 Avent, Inc. Antimicrobial amorphous compositions
US20060093675A1 (en) * 2004-10-29 2006-05-04 Mathew Ebmeier Intravaginal treatment of vaginal infections with metronidazole compositions
BRPI0612448A2 (pt) 2005-05-09 2010-11-23 Foamix Ltd composição espumosa de sacarìdeo
FR2890559B1 (fr) * 2005-09-13 2011-06-24 Galderma Sa Mousses dermatologiques a base de metronidazole et emulsions pour la preparation
FR2890560B1 (fr) * 2005-09-13 2011-06-24 Galderma Sa Mousses dermatologiques a base de metronidazole et emulsions pour leur preparation
WO2007127236A2 (en) 2006-04-28 2007-11-08 Acrymed, Inc. Antimicrobial site dressings
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
WO2009069006A2 (en) 2007-11-30 2009-06-04 Foamix Ltd. Foam containing benzoyl peroxide
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
WO2010041141A2 (en) 2008-10-07 2010-04-15 Foamix Ltd. Oil-based foamable carriers and formulations
CA2709199A1 (en) 2007-12-21 2009-07-02 Galderma Laboratories, Inc. Pre-surgical treatment
AU2009205314A1 (en) 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US7893097B2 (en) 2008-02-02 2011-02-22 Dow Pharmaceutical Sciences, Inc. Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water
US20100105750A1 (en) * 2008-10-23 2010-04-29 Nycomed Us Inc. Stable metronidazole gel formulations
US20120087872A1 (en) 2009-04-28 2012-04-12 Foamix Ltd. Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
CA2769677A1 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
AU2010302350B2 (en) 2009-10-02 2015-06-18 Journey Medical Corporation Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
EP2329849B1 (en) 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
CN103298472A (zh) 2010-03-26 2013-09-11 盖尔德马研究及发展公司 安全和有效治疗红斑的改进的方法和组合物
WO2011117378A2 (en) 2010-03-26 2011-09-29 Galderma Research & Development Improved methods and compositions for safe and effective treatment of telangiectasia
US12661407B2 (en) 2010-04-08 2026-06-23 Journey Medical Corporation Compositions, gels and foams with rheology modulators and uses thereof
RU2587041C2 (ru) 2010-06-30 2016-06-10 Галдерма Ресерч Энд Девелопмент Способ предотвращения или лечения опухоли кожи
AU2011273509A1 (en) 2010-06-30 2013-06-13 Galderma Research & Development Use of alpha-adrenergic receptor agonist for preventing or treating skin tumor
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
ES2498217T5 (es) 2010-10-21 2018-03-19 Galderma S.A. Composición en forma de gel basada en brimonidina
AU2012275292B2 (en) 2011-06-28 2015-11-12 Chemo Research, S.L. High dosage mucoadhesive metronidazole aqueous-based gel formulations their use to treat bacterial vaginosis
WO2013016072A1 (en) 2011-07-22 2013-01-31 Allergan, Inc. Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases
WO2013057579A2 (en) 2011-10-19 2013-04-25 Galderma Pharma S.A. Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors
PH12014500785A1 (en) 2011-10-19 2014-05-12 Galderma Sa Method for treating capillary hemangiomas
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
UA109359C2 (xx) 2011-11-10 2015-08-10 Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
WO2014113493A1 (en) 2013-01-16 2014-07-24 Emory University Cas9-nucleic acid complexes and uses related thereto
CN105209049B (zh) 2013-05-02 2019-05-14 医学科技研究公司 抗微生物组合物及其制造方法
KR102221499B1 (ko) 2013-09-26 2021-03-02 갈데르마 소시에떼아노님 위축성 피부 흉터를 치료하기 위한 프로스타글라딘 F2α 및 그 유사체
US10117911B2 (en) 2015-05-29 2018-11-06 Agenovir Corporation Compositions and methods to treat herpes simplex virus infections
AU2017241767B2 (en) 2016-03-28 2021-07-22 Allergan, Inc. Phenyl urea derivatives as N-formyl peptide receptor modulators
MX2020012139A (es) 2016-09-08 2021-01-29 Vyne Pharmaceuticals Inc Composiciones y metodos para tratar rosacea y acne.
CN110314133A (zh) * 2019-06-28 2019-10-11 石家庄四药有限公司 一种甲硝唑氯化钠注射液及其制备方法
EP4192431A1 (en) 2020-08-04 2023-06-14 Venthera, Inc. Formulations of phosphoinositide 3-kinase inhibitors
CA3255435A1 (en) 2022-05-20 2023-11-23 Dermbiont, Inc. Compositions and formulations allowing the use of a PK inhibitor for the prevention, treatment, and improvement of skin diseases, conditions, and disorders

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032645A (en) 1975-06-19 1977-06-28 G. D. Searle & Co. Injectable metronidazole composition
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4837378A (en) * 1986-01-15 1989-06-06 Curatek Pharmaceuticals, Inc. Topical metronidazole formulations and therapeutic uses thereof
DE3773383D1 (de) * 1987-03-20 1991-10-31 Curatek Pharmaceuticals Neue topische metronidazol-formulierungen.
US5536743A (en) 1988-01-15 1996-07-16 Curatek Pharmaceuticals Limited Partnership Intravaginal treatment of vaginal infections with buffered metronidazole compositions
EP0335545B2 (en) 1988-03-29 1998-09-23 University Of Florida Pharmaceutical formulations for parenteral use
US5997856A (en) 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
TW200402B (enExample) 1990-08-13 1993-02-21 Senju Pharma Co
DE69232535T4 (de) * 1991-06-24 2003-09-11 Hcell Technology, Inc. In langzeitkultur gehaltene hormon-absondernde pankreatische zellen
US5747341A (en) * 1991-06-24 1998-05-05 Pacific Biomedical Research, Inc. Culture media having low osmolarity for establishing and maintaining hormone-secreting cells in long-term culture
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5298410A (en) * 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
JPH07157440A (ja) * 1993-10-15 1995-06-20 Takeda Chem Ind Ltd 医薬用組成物
FR2722098B1 (fr) 1994-07-06 1996-08-23 Cird Galderma Nouveaux medicaments a base de metro-nidazole ou d'un melange synergetique de metronidazole et de clindamycine
KR20010023256A (ko) * 1997-08-27 2001-03-26 헥살 아게 용해도와 생체 이용성이 개선된 신규의 멜록시캄 의약조성물
US5989523A (en) * 1998-03-20 1999-11-23 Fitzjarrell; Edwin A. Topical spray for treating acne containing niacinamide and NaPCA
WO2000015224A1 (en) * 1998-09-17 2000-03-23 Eli Lilly And Company Protein formulations
US6183766B1 (en) * 1999-02-12 2001-02-06 The Procter & Gamble Company Skin sanitizing compositions
EP1383445A4 (en) * 2001-03-20 2005-04-13 Cydex Inc FORMULATIONS WITH PROPOFOL AND A SULFOALKYL ETHER CYCLODEXTRIN
US6881726B2 (en) * 2001-12-24 2005-04-19 Dow Pharmaceutical Sciences Aqueous compositions containing metronidazole

Also Published As

Publication number Publication date
JP2004515463A (ja) 2004-05-27
AR030245A1 (es) 2003-08-13
DE60144520D1 (de) 2011-06-09
EP1303541B1 (en) 2011-04-27
JP4130358B2 (ja) 2008-08-06
EP1303541A4 (en) 2007-01-31
CA2405072C (en) 2007-08-28
EP1303541A1 (en) 2003-04-23
ES2365322T3 (es) 2011-09-29
US6468989B1 (en) 2002-10-22
WO2002006349A1 (en) 2002-01-24
CA2405072A1 (en) 2002-01-24
AU2001269937A1 (en) 2002-01-30

Similar Documents

Publication Publication Date Title
DE60144520D1 (de) Zusammensetzungen enthaltend metronidazol
ATE481105T1 (de) Wässrige zusammensetzungen mit metronidazol
ATE303787T1 (de) Schergelzusammensetzungen
DE60139185D1 (de) Vernetzbare perfluoroelastomarzusammensetzung
AR028197A1 (es) Composiciones antitranspirantes
IS2932B (is) Fúlvestrant samsetning
ATE372372T1 (de) Zusammensetzungen enthaltend cyclodextrin
FI20010780A0 (fi) Parannetut koostumukset
NO20030472D0 (no) Imidazolderivater
DE60227966D1 (de) Harzzusammensetzung enthaltend artikel
IS6915A (is) Lyfjablanda
BR0210619A (pt) composição
IS7081A (is) Lyfjablanda
DE10196796T1 (de) Apatit-verstärkte Harz-Zusammensetzung
ATE369830T1 (de) Schweisshemmende zusammensetzungen
ATE314049T1 (de) Schweisshemmende zusammensetzungen
DE60134551D1 (de) Harzzusammensetzung
DE60137941D1 (de) Polymerzusammensetzung
DE60116858D1 (de) Zusammensetzung
DE60103292D1 (de) Fungizide zusammensetzungen
DE60230349D1 (de) Verbesserte Polymerzusammensetzung
NO20031316L (no) Beleggsammensetninger
EP1311638A4 (en) Coating compositions
DE60115585D1 (de) Harzzusammensetzung
NO20023976L (no) Endoparasittiske sammensetninger

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties